Searched for
GREVLIMID REVENUE
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...
- Cipla shares slide 5% after drug major's Q3 net profit drops 57% YoYCipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Re...
- Q3 results today: Eternal among 59 companies to report earnings on WednesdayIndian markets brace for a busy earnings day with 59 companies reporting Q3 results. Investors are keenly watching Eternal's expected stron...
- Dr Reddy's Q3 preview: PAT may fall 22% YoY as US pressure to weigh on earningsDr Reddy's Laboratories anticipates a subdued performance for the December quarter. Pressure from its United States business is expected to...
- Can US generics momentum and CDMO strength keep pharma earnings steady this quarter?Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive perf...
- Drug companies set for improved revenue growth in June quarter amid US market challengesIndian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. H...
- DRL gears up for biosimilar push, consumer health growth post record FY25Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...
- Dr Reddy’s Labs Q4 Preview: PAT may jump up to 12% YoY, revenue to rise up to 18% on generics business doseDr Reddy’s Q4FY25 net profit is expected to grow 1.3–12% YoY, with revenues likely rising 13–18% to ₹7,981–8,424 crore, according to broker...
- Dr. Reddy's Q3 Preview: PAT may rise 10% YoY; US sales to be stableDr. Reddy's net profit for the third quarter is expected to grow 10% YoY, with revenues likely increasing 13% YoY, based on an average of f...
- Dr Reddy's Labs Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fallAnalysts project U.S. revenue at $419 million, supported by a strong contribution from gRevlimid. The India business is expected to grow 19...
- Dr Reddy's Q1 Preview: PAT may fall 4% YoY on pricing pressure, subdued US salesIn the preceding March quarter, Dr Reddy's reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue f...
- Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North ...
- Dr Reddy’s Q3 Results Preview: Profit may drop on lower Revlimid sales, higher costsThe drugmaker is expected to report a 1.1% YoY drop in consolidated net profit to Rs 1,247 crore, according to the average of estimates giv...
- Sun facing some clouds is still a buy for analystsShares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% fro...
- Back on the growth wagon: Cipla is a favourite of analysts and this week's stock pickCipla reported an FCF of around Rs 3,400 crore in 2019-20 and is expected to report bigger numbers in the coming years due to increased gro...
Load More
